Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30419519 | 1.00 | ABHD6 (0.63) | ABHD6ESR2NR1H2HDAC1DDB1 | |
| SCHEMBL12540273 | 0.88 | ESR2 (0.60) | ABHD6ESR2NR1H2DDB1CRBN | |
| SCHEMBL29712352 | 0.88 | ESR2 (0.60) | ABHD6ESR2NR1H2DDB1CRBN | |
| SCHEMBL29508093 | 0.88 | ESR2 (0.60) | ABHD6ESR2NR1H2HDAC1MAPK1 | |
| SCHEMBL867858 | 0.88 | ESR2 (0.60) | ABHD6ESR2NR1H2HDAC1MAPK1 | |
| SCHEMBL13779817 | 0.86 | NR1H2 (0.52) | ABHD6ESR2NR1H2HDAC1DDB1 | |
| SCHEMBL31460221 | 0.86 | ESR2 (0.54) | ABHD6ESR2NR1H2HDAC1DDB1 | |
| SCHEMBL30707038 | 0.86 | ESR2 (0.54) | ABHD6ESR2NR1H2HDAC1DDB1 | |
| SCHEMBL22169252 | 0.84 | ESR2 (0.48) | ABHD6ESR2NR1H2HDAC1DDB1 | |
| SCHEMBL26618420 | 0.84 | ABHD6 (0.46) | ABHD6ESR2NR1H2DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092076-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4695243-A1 | NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-4662208-A1 | COMPOUNDS AND COMPOSITIONS FOR SELECTIVE DEGRADATION OF ENGINEERED PROTEINS | Celgene Corporation (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| WO-2025085848-A1 | ANTIBACTERIAL COMPOUNDS | ARREPATH, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2025-01-09 | — | — | US | disclosed |
| US-12129263-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2024-10-29 | — | — | US | disclosed |
| WO-2024213552-A1 | NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-10-17 | — | — | WO | disclosed |
| US-20240327381-A1 | Compounds and Compositions for Selective Degradation of Engineered Proteins | CELGENE CORPORATION (US) | 2024-10-03 | — | — | US | disclosed |
| US-9266855-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-02-23 | — | — | US | disclosed |
| US-20160016932-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-21 | — | — | US | disclosed |
| WO-2015007669-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015007669-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | WO | disclosed |
| US-20150025065-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| US-20150025065-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| US-20150025065-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| EP-2621914-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | Abbott GmbH & Co. KG (DE) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012041814-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2012-04-05 | — | — | WO | disclosed |
| US-20120077840-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | ABHD6 3185/4885ESR2 1633/4885NR1H2 3628/4885 |
| US-20160016932-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | GSK3B, GSK3A, GYS2 | ABHD6 3324/4885ESR2 1571/4885NR1H2 965/4885 |
| US-20120077840-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | GSK3B, GSK3A, GYS2 | ABHD6 3324/4885ESR2 1571/4885NR1H2 965/4885 |
| US-20150025065-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | PRKAR2B, PRKAB1, PRKAB2 | ABHD6 3410/4885ESR2 440/4885NR1H2 1407/4885 |
| US-20240327381-A1 | Compounds and Compositions for Selective Degradation of Engineered Proteins | TP53, APC, MDM2 | ABHD6 1359/4885ESR2 2223/4885NR1H2 3982/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | ABHD6 3436/4885ESR2 893/4885NR1H2 1173/4885 |
| US-12129263-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | ABHD6 3185/4885ESR2 1633/4885NR1H2 3628/4885 |
| US-20260092076-A1 | NOVEL COMPOUNDS | NOD1, NLRP3, ARRB1 | ABHD6 2778/4885ESR2 732/4885NR1H2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.